Of specific interest for the current study is the fact that JAM-A expression is high in the human epidermal growth factor receptor-2 (HER2) genomic subtype of invasive breast cancer, and that JAM-A levels have been shown to influence those of HER2 at both transcriptional and translational levels in breast cancer cells in vitro [8,10]. The gene discussed is ERBB2; the disease is breast carcinoma.